In summary, we describe high YAP1/TAZ activity as a molecular driver of MAPKi-resistant MITFlow/AXLhigh melanomas and identify SLC35B2 as a single target for overcoming broad compensatory pathway activation through limiting RTK activity. This evidence concerns the gene SLC35B2 and melanoma.